PYX Resources: Achieving volume and diversification milestones. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Will move later on today once everyone has digested the results and 2.4 million more revenue on the contract
Great to see....this will get to 40p very quickly....multi bagger watch this space
Leaderboard now
Scope expanded with top 10 biopharma company
Tue, 4th Dec 2018 07:00
RNS Number : 3018J
IXICO plc
04 December 2018
4 December 2018
IXICO plc
("IXICO" or the "Company")
IXICO signs expanded scope to current contract with top 10 biopharmaceutical company
Increasing contract value by $2.4m over the remaining term
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed an expanded scope to a current contract with a top 10 biopharmaceutical company. Additional services will be provided, increasing the value of the contract by $2.4m over the remaining 6-year term of the agreement. As a result, the contract value has increased from $2.7m to $5.1m.
The expanded scope will see IXICO providing additional imaging services, to a significantly higher number of patients, and an increased number of participating international study sites.
Giulio Cerroni, Chief Executive of IXICO, said: "I am delighted that our client has decided to expand our involvement in this important study. We value the strength of our relationships with biopharmaceutical companies and our ability to provide them with important insights that support their efforts to bring new therapies to market. This latest increase in scope demonstrates IXICO's ability to efficiently scale operations and adapt to changing requirements as global clinical studies progress."
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Officer
Susan Lowther, Chief Financial Officer
Tel: +44 20 3763 7499
Shore Capital (Nomad and Broker)
Edward Mansfield/Anita Ghanekar/Daniel Bush
Tel: +44 20 7408 4090
FTI Consulting Limited (Investor Relations)
Simon Conway/Mo Noonan
Tel: +44 20 3727 1000
Excellent news today...30p coming later today
The leaderboard now
This is a little gem and well under the radar
20% up already
Should fly today. Very impressive results and contracts. well done!
Ixi our presenting at Proactive Investors One2one in London on 24th Jan.
Looking forward to a good update on 4th December.
News will send this flying have lots in the pipeline
Till next update ... good time to buy
In here....multi bagger buying at today price....under valued
Yes I am hopeful that it will multi bag and probably be taken over in the future, we seem to be making excellent progress but it will still take a year or two.
Is this share.... a multi bagger in the making
We will be 50p + with new contracts and results
In advance of results and new deals coming through
Expected December 4th worth a buying before hand
Should start to see a rise in the run up to results
can't understand why this company doesn't get more interest given is latest trading results which were outstanding.
1 month before results...easy money if you buy now
Ixico has achieved a 32% increase in annual revenues after expanding the range of medical imaging services that it provides, the company said on Monday. For the year ended 30 September, the neuroscience-focused data science outfit saw its revenue jump 32% to £5.4m and secured a number of new multi-year projects which are worth a combined total of more than £15m, including a £9.1m contract to deliver services in a Phase III trial. The new projects include the supply of new services and wearable biosensor projects, from which Ixico has received preliminary revenue. Meanwhile, total income increased by 25% to £6.0m, up from £4.8m in 2017, while other income was in line with the prior year at £0.6m. The AIM traded company had net cash of £7.9m at 30 September, after an over-subscribed placing in May to raise funds for a new commercially-led growth strategy. Notable cash inflows also included a research and development tax credit receipt of £0.4m and reimbursement of grant costs. Analysts at Shore Capital said that the company was "comfortably" ahead of its forecasts having achieved revenue growth of more than 25% for two years running. "We remain enthused by Ixico's progress and view momentum in new contract wins as evidence of continuing success from its renewed focus on a commercially-led growth strategy," said the broker in a note to clients on Monday. Full preliminary results for the year will be released on 4 December.
IXICO plc
15 October 2018
15 October 2018
IXICO plc
("IXICO" or the "Company")
Pre-Close Trading Update for year ended 30 September 2018
Revenue increased by 32% to £5.4m
Strong closing cash balance of £7.9m
IXICO plc (AIM: IXI), the data science company delivering insights in neuroscience, today provides the following pre-close trading update ahead of its preliminary results for the year ended 30 September 2018.
The Company is pleased to announce that revenue increased by £1.3 million or 32% to £5.4 million (2017: £4.1 million). Excluding the impact of foreign exchange, the underlying revenue of £5.1 million (2017: £3.8 million) increased by 34%. This revenue growth included an expansion of medical imaging services provided to global pharmaceutical clients in new and existing projects, together with preliminary revenue from wearable biosensor projects.
During the year the Company announced several new multi-year contracts which are worth a combined total of over £15.0 million, including a Phase III contract signed at the end of the financial year. These new contracts and existing projects, provide a foundation for future revenue growth.
Total income increased by 25% to £6.0 million (2017: £4.8 million) as Other income of £0.6 million (2017: £0.6 million) was in line with the prior year.
Net cash at 30 September 2018 was £7.9 million (2017: £2.4 million) and reflected an over-subscribed placing of £5.5 million in May 2018, which will be used to accelerate the Company's commercially led growth strategy. Second half cash inflows also included R&D tax credit receipt of £0.4 million and reimbursement of grant costs.
The Company anticipates that its preliminary results to 30 September 2018 will be announced on 4 December 2018.
All buys...great RNS..can see this above 40p very soon
Revenues increase by 32 percent